DE602004030604D1 - N-(5-adamantane-1-yl-methoxy-pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz - Google Patents

N-(5-adamantane-1-yl-methoxy-pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz

Info

Publication number
DE602004030604D1
DE602004030604D1 DE602004030604T DE602004030604T DE602004030604D1 DE 602004030604 D1 DE602004030604 D1 DE 602004030604D1 DE 602004030604 T DE602004030604 T DE 602004030604T DE 602004030604 T DE602004030604 T DE 602004030604T DE 602004030604 D1 DE602004030604 D1 DE 602004030604D1
Authority
DE
Germany
Prior art keywords
treatment
insulin resistance
desoxynojirimycin
adamantane
pentyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004030604T
Other languages
English (en)
Inventor
Johannes Maria Aerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of DE602004030604D1 publication Critical patent/DE602004030604D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004030604T 2003-10-29 2004-10-29 N-(5-adamantane-1-yl-methoxy-pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz Active DE602004030604D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03078396 2003-10-29
EP04076936 2004-07-06
PCT/NL2004/000760 WO2005039578A2 (en) 2003-10-29 2004-10-29 Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof

Publications (1)

Publication Number Publication Date
DE602004030604D1 true DE602004030604D1 (de) 2011-01-27

Family

ID=34524734

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004030604T Active DE602004030604D1 (de) 2003-10-29 2004-10-29 N-(5-adamantane-1-yl-methoxy-pentyl)desoxynojirimycin oder eines pharmazeutischen salzes davon zur verwendung bei der behandlung der insulinresistenz

Country Status (11)

Country Link
US (1) US7662838B2 (de)
EP (1) EP1680112B1 (de)
JP (1) JP2007509925A (de)
AT (1) ATE491451T1 (de)
AU (1) AU2004283631A1 (de)
CA (1) CA2544086A1 (de)
DE (1) DE602004030604D1 (de)
IL (1) IL175259A0 (de)
PL (1) PL1680112T3 (de)
PT (1) PT1680112E (de)
WO (1) WO2005039578A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1528056A1 (de) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin Derivate und ihre Verwendung als Glukosesylceramidase-Inhibitoren
US20060025449A1 (en) * 2004-03-25 2006-02-02 United Therapeutics Use of N-substituted imino sugars for appetite suppression
CA2586761A1 (en) 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
FR2887549B1 (fr) * 2005-06-23 2009-07-10 Centre Nat Rech Scient Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation
ES2546181T3 (es) 2006-05-09 2015-09-21 Genzyme Corporation Métodos de tratar la enfermedad del hígado graso mediante inhibición de la síntesis de glucoesfingolípidos
GB0614098D0 (en) * 2006-07-15 2006-08-23 Mnl Pharma Ltd Immune response variegation with imino sugars
JP2008104399A (ja) * 2006-10-25 2008-05-08 Spirulina Biological Lab Ltd 糖尿病予防食品
EP2594565B1 (de) 2007-05-31 2018-10-24 Genzyme Corporation Glukosylceramid-Synthase-Hemmer vom 2-Acylaminpropanol-Typ
KR20160085917A (ko) 2007-10-05 2016-07-18 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
CN102271678B (zh) 2008-10-03 2017-06-30 简詹姆公司 2‑酰胺基丙醇型葡糖神经酰胺合成酶抑制剂
CA2793276A1 (en) * 2009-03-27 2010-09-30 Zacharon Pharmaceuticals, Inc. Ganglioside biosynthesis modulators
US20140227371A1 (en) * 2011-07-13 2014-08-14 Alan David Heath Edible composition
US9623016B2 (en) 2013-03-15 2017-04-18 Emergent Virology Llc Antibacterial compounds
WO2022227287A1 (zh) * 2021-04-25 2022-11-03 中南大学 Dnj及其衍生物在制备预防和/或治疗肺动脉高压药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2504000B2 (ja) 1986-09-02 1996-06-05 日本新薬株式会社 グルコシルモラノリン誘導体
US6177447B1 (en) * 1996-07-15 2001-01-23 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
BR9902585A (pt) * 1999-02-11 2000-09-26 Claudio Cerqueira Lopes Um novo processo de sìntese de aza-açúcares com atividade biológica
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
US6235737B1 (en) 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
US20040204379A1 (en) 2000-06-19 2004-10-14 Cheng Seng H. Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US20030100504A1 (en) * 2001-10-15 2003-05-29 Genentech, Inc. Treatment and diagnosis of insulin-resistant states
EP1528056A1 (de) * 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin Derivate und ihre Verwendung als Glukosesylceramidase-Inhibitoren
WO2005063706A1 (en) 2003-12-23 2005-07-14 Macrozyme Dnm B.V. Synthesis of nojirimycins
US9181184B2 (en) 2005-05-17 2015-11-10 Amicus Therapeutics, Inc. Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives

Also Published As

Publication number Publication date
ATE491451T1 (de) 2011-01-15
EP1680112A2 (de) 2006-07-19
EP1680112B1 (de) 2010-12-15
CA2544086A1 (en) 2005-05-06
PT1680112E (pt) 2011-03-24
US20070135487A1 (en) 2007-06-14
US7662838B2 (en) 2010-02-16
WO2005039578A3 (en) 2005-09-29
AU2004283631A1 (en) 2005-05-06
IL175259A0 (en) 2006-09-05
PL1680112T3 (pl) 2011-05-31
JP2007509925A (ja) 2007-04-19
WO2005039578A2 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
IL175259A0 (en) Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
DE60323090D1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
CY1115484T1 (el) Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
DE602004029580D1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
EP2371853A3 (de) Insulinderivate oder pharmazeutisch verträgliches Salz davon, pharmazeutische Zusammensetzung, Verwendung von Insulinderivat oder pharmazeutisch verträglichem Salz davon und Behandlungsverfahren
JP2009500045A5 (de)
TW200637544A (en) Medicaments for the treatment or prevention of fibrotic diseases
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
ATE541567T1 (de) Pharmazeutische zusammensetzung zur prävention und behandlung von metabolischen knochenerkrankungen mit alpha-arylmethoxyacrylat- derivaten
EA200800075A1 (ru) Схема дозирования для празугреля
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
DE602004026578D1 (de) Neue pharmazeutische verwendungen von staurosporin-derivaten
DE60302431D1 (de) Methode zur behandlung eines analgesiebedürftigen patienten
DE602004030048D1 (de) Ffizienz
DE60212349D1 (de) Verwendung von n-acetyl-d-glucosamin bei der herstellung eines pharmazeutischen mittels zur prävention und behandlung von sexuellen störungen
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
DE602006016168D1 (de) 1,3,5-triazepin-dionen zur Behandlung von Malaria
ATE499945T1 (de) Pharmazeutische zusammensetzung zur behandlung von invasiver lungenaspergillose
DE502007006951D1 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen